TNFRSF10B and neoplasm: By using a bsAb directed against TRAIL-R2 as TAA and the T cell receptor associated CD3 as triggering molecule, we were able to induce the killing of cancer cells grown in a pro-tumor microenvironment using autologous lymphocytes mimicking a real human in vivo situation [10, 29].